NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023

NEW YORK, Aug. 4, 2023

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/novocure-class-action-loss-submission-form/?id=42950&from=4

The lawsuit seeks to recover losses for shareholders who purchased NovoCure between January 5, 2023 and June 5, 2023.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until August 18, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, NovoCure Limited issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company's regulatory prospects and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887